aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution
21 mars 2023 08h00 HE
|
aTyr Pharma, Inc.
Findings confirm LTBP1, a key regulator of TGF-β, as binding partner for tRNA synthetase DARS fragment ATYR0101 Data indicates ATYR0101 may have therapeutic potential for fibrotic pathologies...
aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment
15 déc. 2022 08h00 HE
|
aTyr Pharma, Inc.
LTBP1 is key regulator of TGF-β, a major driver of fibrosis. Latest target identified from company’s platform in collaboration with Dualsystems Biotech AG. SAN DIEGO, Dec. 15, 2022 (GLOBE...